PDF-HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include

FULL PRESCRIBING INFORMATION INDICATIONS AND USAGE Jakafi is indicated for treatment of patients with intermediate or highrisk. See full prescribing information for BIOTHRAX BIOTHRAX Anthrax Vaccine Adsorbed Suspension for Intramuscular or Subcutaneous Injection Initial US Approval 1970 RECENT MAJOR CHANGES DOSAGE AND ADMINISTRATION 21 May2012 INDICATIONS AND USAGE Bacillu See full prescribing information for Ferric Citrate Ferric Citrate ablet containing 210 mg of ferric iron equivalent to 1 g ferric citrate for ral se Initial U Approval 2014 INDICATIONS AND USAGE Ferric Citrate s a phosphate binder indicated for See full prescribing information for LATISSE LATISSE bimatoprost ophthalmic solution 003 Initial US Approval 2001 INDICATIONS AND USAGE LATISSE is a prostaglandin analog indicated to treat hypotrichosis of the eyelashes by increasing their growth --------------------------RECENT MAJOR CHANGES---------------------------- Boxed Warning 04/15 Indications and Usage (1.1) 04/15 Dosage and Administration (2.1, 2.2) 04/15 Warnings a FULL PRESCRIBING INFORMATION INDICATIONS AND USAGE SOMA is indicated for the relief of discomfort associated with acute, painful itions in adults. SOMA should only be used for short periods (up to two Adults and Children 30 kg (66 lbs) or more: 0.3 to 0.5 mg (0.3 to 0.5 mL) intramuscularly or subcutaneously into anterolateral aspect of the thigh every 5 to 10 minutes as necessary (2.1) Children 30 What’s different about paediatric prescribing. Children are just . small adults. NOT!. Vary in their developmental stages. Pre-term, neonates, infants, children, adolescents. Dynamic anatomy and physiology. Marie Bradley*, . Tom Fahey**, . Caitriona. . Cahir. **, Kathleen Bennett***, Dermot O’Reilly****, . Carmel M. Hughes*. Limitation of Use Should only be used for acute treatment periods up to two or three weeks (1)------------------------DOSAGE AND ADMINISTRATION------------------- DESCRIPTIONCLINCIAL PHARMACOLOGY12.1 Dermatologic ToxicityTemporarily interruptPOTELIGEO for moderate or severe skin rashes Permanently discontinue POTELIGEO for lifethreatening rash 51InfusionReactionsTemporarily interruptfor any infusi treatment and adjust dosing as needed 22 51 constipation nausea and vomiting as needed 22 52 Peripheral Neuropathy Monitor patients for symptoms of peripheral neuropathy and adjust dosing as needed 2 Limitations of Use: Due to the possible association between malignancy and calcitoninsalmon use, the need for continued therapy should be reevaluated on a . -------------------------------DRUG INTER EXTRAVASATION AND TISSUE NECROSIS, and SEVERE MYELOSUPPRESSION See full prescribing information for complete boxed warning. Cardiomyopathy: Myocardial damage can occur with doxorubicin HCl with inc Levoleucovorin for injection is not indicated for the treatment of pernicious anemia or megaloblastic anemia secondary to lack of vitamin B because of the risk of progression of neurologic manifestati